Seeking men and women whose multiple myeloma has returned following treatment or did not respond to treatment for a study of an investigational drug.
Participants in this study will be assigned to receive the investigational drug in combination with one of four different usual anti-myeloma treatments. Treatments are given in 28-day cycles and there are additional study visits on day 8, day 15 and day 22 of each cycle during the first 6 months of the study.
What we're hoping for
We are studying whether adding an investigational drug to anti-myeloma treatment is safe and effective for relapsed/refractory multiple myeloma.
ClinicalTrials.gov Identifier: NCT05259839